Analysts have revised their price target for Global Health downward from $1,395.40 to $1,366.20, citing slight reductions in projected revenue growth and profit margins as the main rationale for this adjustment.
What's in the News
- Medanta has initiated construction on a new 400+ bed super-specialty facility in Guwahati. The facility aims to deliver world-class healthcare and advanced robotic procedures to the Northeastern region at an estimated cost of Rs 500 crores (Key Developments).
- The new Guwahati facility will offer a comprehensive range of specialties, including transplant programs, cardiology, neurology, oncology, and preventive health check-ups (Key Developments).
- The project is expected to create between 5,000 and 7,000 direct and indirect jobs, boosting employment and socio-economic progress in the area (Key Developments).
- The Board of Directors will meet on November 7, 2025, to review and approve the company’s unaudited financial results for the quarter and half-year ending September 30, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased modestly from ₹1,395.40 to ₹1,366.20.
- Discount Rate remains unchanged at 12.76%.
- Revenue Growth estimate has edged down slightly from 15.36% to 15.22%.
- Net Profit Margin is now projected at 15.89%, down from 16.02%.
- Future P/E ratio has declined marginally from 54.65x to 54.31x.
Have other thoughts on Global Health?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.